• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

byMinjee Kim
October 20, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo.

2. Overall survival was significantly higher in nivolumab plus ipilimumab compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Melanoma is a form of skin cancer with the aggressive potential to metastasize to other organs of the body. This study assessed the use of immune checkpoint inhibitors in patients with previously resected stage IV melanoma and no current evidence of disease. Patients were randomly assigned to either a regimen of nivolumab plus ipilimumab, nivolumab alone, or placebo, for up to 1 year. Both the nivolumab-ipilimumab and nivolumab monotherapy groups showed significantly improved 4-year recurrence-free survival compared to placebo. Overall survival was additionally improved in the nivolumab plus ipilimumab group compared to placebo. Adverse events were consistent with previously described for the two drugs. Limitations of the IMMUNED trial include the study size. Nonetheless, the IMMUNED trial demonstrates the clinical benefit of nivolumab and ipilimumab in patients with stage IV melanoma with no evidence of disease.

Click to read the study in The Lancet

Relevant Reading: Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

RELATED REPORTS

#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma

In-Depth [randomized controlled trial]: IMMUNED was a phase 2 drug trial that took place across 20 academic medical centres in Germany. Patients were eligible if they were aged 18-80 years and had previous stage IV cutaneous or unknown primary melanoma with no evidence of disease after radiotherapy or surgery. A total of 167 patients were randomized 1:1:1 to either nivolumab plus ipilimumab (n=56), nivolumab plus ipilimumab-matching placebo (n=59), or double placebo control (n=52). Treatment regimen was nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab 3 mg/kg every 2 weeks, nivolumab alone every 2 weeks, or matching placebo, for up to 1 year. The primary endpoint was recurrence-free survival. The median follow-up time was 49.2 months. The 4-year recurrence-free survival was highest in the nivolumab plus ipilimumab group (64.2%), followed by nivolumab alone (31.4%), and then placebo (15.0%). Compared to placebo, the hazard ratio for recurrence for the nivolumab plus ipilimumab group was 0.25 (97.5% CI 0.13-0.48, p<0.0001). For overall survival between nivolumab plus ipilimumab group versus placebo, the hazard ratio was 0.41 (p=0.04). There were no deaths related to the treatment. Grade 3-4 adverse events occurred in 71% of the nivolumab plus ipilimumab group compared to 29% of the nivolumab alone group.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced melanomaIMMUNED trialipilimumabmelanomaNivolumabnivolumab-ipilimumabskin cancer
Previous Post

Scoop thrombectomy safe and effective as a novel technique for treating thrombosed arteriovenous fistulas

Next Post

Wellness Check: Sleep

RelatedReports

#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest
StudyGraphics

#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

December 22, 2022
Choosing Wisely campaign releases recommendations in newborn medicine
Oncology

Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

December 28, 2022
Complement mutation linked to poor response to eculizumab
Oncology

Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma

December 28, 2022
#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma
StudyGraphics

#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma

November 17, 2022
Next Post
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Wellness Check: Sleep

Study explores effects of daily iron supplementation in 2- to 5-year-olds

Endovascular thrombectomy improves functional outcomes in adults with basilar-artery occlusions

Parental debt influences child socioemotional well-being

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve diabetes outcomes but are not cost effective

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options